Japan's troubled automaker Nissan banks on hybrid EV technology
Reporters try out Nissan's e-Power electrification technology on the current Qashqai model at the company's Grandrive facility in Yokosuka, Japan, outside Tokyo, Monday, May 26, 2025. (AP Photo/Yuri Kageyama)
YOKOSUKA, Japan — Money-losing Japanese automaker Nissan is banking on its latest 'e-Power' technology for a turnaround.
A kind of hybrid, e-Power comes equipped with both an electric motor and gasoline engine, much like the Toyota Motor Corp. Prius. It's different from a Prius in that it doesn't switch back and forth between the motor and engine during the drive.
That means the car always is running on its EV battery, ensuring a quiet, smooth ride.
'Nissan has a proud history of pioneering innovative technology that set us apart,' Chief Technology Officer Eiichi Akashi told reporters on the sidelines of a test drive at its Grandrive course outside Tokyo.
The advantage of e-Power vehicles is that they never need to be charged like EVs do. The owner just fuels up at a gas station and the car never runs out of a charge.
Nissan Motor Corp., which racked up a $4.5 billion loss for the fiscal year through March, sorely needs a hot-seller, especially in the lucrative North American market. But the U.S. market is proving a big headache for all the Japanese automakers because of President Donald Trump's tariff policies.
To achieve a turnaround, Nissan is working on reducing costs, strengthening business partnerships and redefining its lineup. That's where e-Power fits in, according to Akashi.
Yokohama-based Nissan announced earlier this month that it's slashing about 15% of its global work force, or about 20,000 employees, and reducing the number of its auto plants to 10 from 17, under an ambitious recovery plan led by its new Chief Executive Ivan Espinosa.
Nissan officials did not give a price for the upcoming e-Power models. The only other automaker offers a similar technology is 'kei,' or tiny car manufacturer Suzuki Motor Corp.
E-Power is already offered on the Nissan Qashqai and X-Trail model in Europe, and the Note in Japan. The upgraded version will be offered in the new Rogue in the U.S.
Nissan, a pioneer in EVs with its Leaf, which went on sale in 2010, is also preparing beefed up EV models. It's also working on a solid-state battery which is expected to replace the lithium-ion batteries now widely used in hybrids, EVs and e-Power models.
Analysts say Nissan is in danger of running out of cash and needs a partner. Speculation is rife its Yokohama headquarters building will get sold, or one of its Japan plants will be turned into a casino.
Nissan started talks last year with Japanese rival Honda Motor Co. for a business integration but announced in February that it was dropping the talks.
Yuri Kageyama, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Better EV Stock: Ford vs. Tesla
-The comparison between Ford (NYSE: F) and Tesla (NASDAQ: TSLA) is valuable and valid because it speaks to where the auto industry is headed and highlights the relative position of each company as it moves toward electric vehicles and robotaxis. Whether it's a legacy automaker (Ford) or a dedicated battery electric vehicle company(Tesla), the key opportunities and challenges are the same. So, which company is better placed to thrive in the future? Affordable electric vehicles and robotaxis Tesla's launch of its full-self-driving (FSD) robotaxi is sometimes seen as a tactical move as its electric vehicle (EV) sales and market share come under pressure in 2025, but nothing could be further from the truth. The reality is that major automakers, including Ford, and leading technology companies have invested billions in robotaxis and autonomous driving, and it's an integral part of the future of the auto industry. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The reason behind the investment is a recognition that robotaxis have huge profit potential, not least because they offer a long stream of recurring income from ride-per-mile revenue. Another reality is that EVs are not cheap, and if they are the future of the auto industry, automakers need to make them more affordable. They also need to offer robotaxis to make mobility more affordable. However, don't take my word for it. Here's Ford's CEO Jim Farley in 2019 on autonomous driving and robotaxis: "The self-driving system is incredibly important to develop, but it's just one part of building a safe and scalable self-driving service that consumers can trust." Farley went on to outline a timeline for a "commercial self-driving service" in 2021, which Ford would fail to achieve. As for affordable EVs, last year, Farley reiterated the need to offer smaller and more affordable EVs to achieve profitability as an EV maker. The two things are strongly connected. You can't have robotaxi EVs if the vehicles aren't affordable. That's a point that resonated during a recent CNBC interview with Waymo, which has a robotaxi service already in place, yet co-CEO Tekedra Mawakana declined to outline a timeline for the company's profitability. Waymo's lack of profitability means its owner, Alphabet, is going to have to invest significant sums, at a loss, if it wants Waymo to build scale. That creates a huge opportunity for a company like Tesla that is just entering the market and potentially offers a much more commercial and scalable service. Tesla's advantage in scaling robotaxis lies in its ability to transform existing Tesla vehicles into robotaxis, as well as its capability to produce a dedicated robotaxi, the Cybercab. Unlike Waymo, Tesla doesn't need to partner with automakers to build scale. Moreover, Musk has disclosed that Tesla has been in discussions about licensing its FSD to other automakers -- another route to long-term profitability. Affordable EVs I'll cut to the chase. If Tesla can make automated driving and robotaxis work, then there's only one winner here, and it's Tesla. First, Ford is a long way from having a profitable EV business. For example, its Model E segment lost $5.1 billion in 2024, and then $849 million in the first quarter of 2025. Ford sold 22,550 EVs in the first quarter, implying it lost almost $38,000 on every EV sold. Moreover, its EV models, the Mustang Mach-E, the F-150 Lightning, and the E-Transit, are far from being affordable EVs. In contrast, Tesla generated $7.1 billion in operating profit in 2024. Despite losing market share amid declining sales, it still dominated the U.S. market, holding 43.5% of the market in the first quarter of 2025. Ford was a distant second with 7.7%. Both Ford and Tesla are planning to release low-cost models in the future, but given Ford's ongoing losses, Tesla's profitability, and its ability to lower its average cost per car, down from above $38,000 in early 2023 to below $35,000 in late 2024, the latter looks far better positioned to do so sustainably. Robotaxis and FSD Ford backed off its robotaxi/FSD plans in 2022, following the shutdown of Argo AI by Ford and Volkswagen after years of heavy investment. The company had been created to develop the technology and received billions of dollars in investment from Ford and Volkswagen. For reference, General Motors has also ended robotaxi development. In contrast, Tesla is preparing for the official launch of its unsupervised FSD/robotaxi service in Austin, Texas, this month, and it may be live by the time you read this article. While the launch will be small and highly contained, it still marks the birth of Tesla's robotaxi offering. Musk believes Tesla will have a dedicated, low-cost robotaxi, the Cybercab, in volume production by 2026. Indeed, Ford may end up licensing FSD from Tesla, and to his great credit, Farley has indicated an openness to partnering on FSD. Ford or Tesla? There is no guarantee that Tesla's robotaxi or FSD will be successful, and investors need to closely monitor events. Moreover, Musk has a history of being overly optimistic on such matters. That said, the major automakers have been and are still pursuing the idea of lower-cost EVs and robotaxis and automated driving, and currently, Tesla remains the best-positioned company to meet those aims. It's where the industry wants to be, and Tesla is in pole position. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 994%* — a market-crushing outperformance compared to 172% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
2 days ago
- Globe and Mail
Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts
Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Canada News.Net
3 days ago
- Canada News.Net
Tariffs push Mitsubishi to raise U.S. vehicle prices by 2.1%
WASHINGTON, D.C.: Mitsubishi Motors is the latest automaker to raise prices in the United States, joining a growing list of car companies adjusting to higher costs triggered by new U.S. import tariffs. The Japanese carmaker said this week it will increase U.S. vehicle prices by an average of 2.1 percent, starting June 18. The move comes after President Donald Trump's administration imposed a 25 percent tariff in April on car imports from Japan and other nations — a decision that briefly halted Mitsubishi's U.S. deliveries. The company confirmed that shipments to dealers, which had been suspended at ports, resumed last week. "This is a direct result of our regular and ongoing review of pricing in order to ensure we are in line with segment expectations," Mitsubishi said in a statement. The company's U.S. sales have been climbing, with a strong performance in 2024 (110,000 units sold — up 26 percent from the previous year) and an 11 percent increase in the first quarter of 2025. Dealers have been informed that the suggested retail price increases won't affect vehicles already in showrooms. Mitsubishi also highlighted ongoing investment in new models and technologies, including updates to the 2025 Outlander, a new EV launch in the U.S., and a potential jointly developed vehicle with Nissan to be built domestically. In May 2025, other carmakers also responded to the tariff pressure: Subaru raised U.S. prices by up to $2,055 on some models, while Ford hiked prices by up to $2,000 on three vehicles produced in Mexico.
